Translation of commensal bacteria mechanism for immunotherapy

共生菌免疫治疗机制的转化

基本信息

  • 批准号:
    10311095
  • 负责人:
  • 金额:
    $ 54.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-12-02 至 2024-11-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Microbiota are associated with remarkable effects on host health and disease. Notably, discrete species of commensal bacteria have been correlated with improved patient responses to cancer immunotherapy. However, the molecular mechanisms underlying the functions of these beneficial bacteria remain poorly understood. In particular, specific strains of Enterococci have been linked with improved response to anti-PD-1/PD-L1 treatment in patients with metastatic melanoma, lung, and kidney cancers, but their mechanism of action has not been elucidated nor employed to improve cancer immunotherapy. Recent work from the Hang laboratory has demonstrated that these beneficial strains of Enterococci have unique peptidoglycan composition and remodeling enzymes. Based on these studies, this project hypothesizes that specific strains of Enterococci may prime innate immune signaling pathways and enhance anti-PD-1/PD-L1 immunotherapy against metastatic cancers. To evaluate the activity and mechanism(s) of Enterococci during immunotherapy as well as co-opt their protective factors for cancer immunotherapy, this proposal will examine how specific Enterococci strains alter cancer growth, immune cell populations, and microbiota composition in mouse models of cancer immunotherapy. In addition, the Hang laboratory will identify Enterococci protective factors and engineer them into existing human probiotics to translate our basic microbiota-cancer immunotherapy findings into novel therapeutic agents. Finally, the Hang laboratory will also synthesize novel immunomodulatory small molecules that activate host pathways used by Enterococci to enhance cancer immunotherapy. These studies will reveal fundamental microbiota- cancer immunotherapy mechanisms and develop new therapeutic strategies and agents to enhance cancer immunotherapy.
项目摘要 微生物群与宿主健康和疾病的显着影响有关。值得注意的是, 肠道细菌与改善患者对癌症免疫疗法的反应有关。然而,在这方面, 对这些有益细菌功能的分子机制仍然知之甚少。在 特别是,肠球菌的特定菌株与抗PD-1/PD-L1治疗的应答改善有关 在转移性黑色素瘤、肺癌和肾癌患者中,但其作用机制尚不清楚。 也不用于改善癌症免疫疗法。Hang实验室最近的工作 证明了这些有益的肠球菌菌株具有独特的肽聚糖组成, 重塑酶基于这些研究,本项目假设肠球菌的特定菌株可能 启动先天免疫信号传导通路,增强抗PD-1/PD-L1免疫治疗, 癌的评价肠球菌在免疫治疗中的活性和作用机制, 癌症免疫治疗的保护因素,这项提案将研究特定的肠球菌菌株如何改变 癌症免疫治疗小鼠模型中的癌症生长、免疫细胞群体和微生物群组成。 此外,Hang实验室将鉴定肠球菌保护因子,并将其工程化到现有的人体内。 益生菌将我们的基本微生物群-癌症免疫治疗发现转化为新的治疗药物。最后, Hang实验室还将合成激活宿主途径新型免疫调节小分子 用于增强癌症免疫治疗。这些研究将揭示基本的微生物群- 癌症免疫治疗机制和开发新的治疗策略和药剂,以提高癌症 免疫疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Howard C Hang其他文献

Howard C Hang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Howard C Hang', 18)}}的其他基金

Microbiota, Probiotic and Dietary Metabolite Control of Enteric Pathogen Virulence
微生物群、益生菌和膳食代谢物对肠道病原体毒力的控制
  • 批准号:
    10562497
  • 财政年份:
    2022
  • 资助金额:
    $ 54.42万
  • 项目类别:
Distal gut microbiome targets of host anti-proteolytic proteins during colitis
结肠炎期间宿主抗蛋白水解蛋白的远端肠道微生物组目标
  • 批准号:
    10320030
  • 财政年份:
    2020
  • 资助金额:
    $ 54.42万
  • 项目类别:
Translation of commensal bacteria mechanism for immunotherapy
共生菌免疫治疗机制的转化
  • 批准号:
    10533309
  • 财政年份:
    2019
  • 资助金额:
    $ 54.42万
  • 项目类别:
Translation of commensal bacteria mechanism for immunotherapy
共生菌免疫治疗机制的转化
  • 批准号:
    10064132
  • 财政年份:
    2019
  • 资助金额:
    $ 54.42万
  • 项目类别:
Translation of commensal bacteria mechanism for immunotherapy
共生菌免疫治疗机制的转化
  • 批准号:
    10379772
  • 财政年份:
    2019
  • 资助金额:
    $ 54.42万
  • 项目类别:
Elucidation of Commensal Bacteria Mechanisms Required for Host Protection
阐明宿主保护所需的共生细菌机制
  • 批准号:
    9894505
  • 财政年份:
    2013
  • 资助金额:
    $ 54.42万
  • 项目类别:
Elucidation of Commensal Bacteria Mechanisms Required for Host Protection
阐明宿主保护所需的共生细菌机制
  • 批准号:
    8594254
  • 财政年份:
    2013
  • 资助金额:
    $ 54.42万
  • 项目类别:
Elucidation of Commensal Bacteria Mechanisms Required for Host Protection
阐明宿主保护所需的共生细菌机制
  • 批准号:
    8412902
  • 财政年份:
    2013
  • 资助金额:
    $ 54.42万
  • 项目类别:
Studies on Protein Lipidation
蛋白质脂化研究
  • 批准号:
    9707092
  • 财政年份:
    2010
  • 资助金额:
    $ 54.42万
  • 项目类别:
Studies on Protein Lipidation
蛋白质脂化研究
  • 批准号:
    9279154
  • 财政年份:
    2010
  • 资助金额:
    $ 54.42万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 54.42万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 54.42万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 54.42万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 54.42万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 54.42万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 54.42万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 54.42万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 54.42万
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 54.42万
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 54.42万
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了